Heng Zhou

BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints

Heng Zhou, Ying Yuan · Statistics in Medicine · 2017 · 127 citations

Public Health, Biostatistics, Bayesian Biostatistics +15

Accuracy, Safety, and Reliability of Novel Phase I Trial Designs

Heng Zhou, Ying Yuan, Lei Nie · Clinical Cancer Research · 2018 · 121 citations

Pharmacy, Biostatistics, Pharmacology +13

Bayesian optimal phase <scp>II</scp> clinical trial design with time‐to‐event endpoint

Heng Zhou, Cong Chen, Linda Sun et al. · Pharmaceutical Statistics · 2020 · 34 citations

Public Health, Biostatistics, Bayesian Biostatistics +16

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Víctor Moreno, Emiliano Calvo, Mark R. Middleton et al. · Cancer Immunology Immunotherapy · 2022 · 33 citations · Full text

Medicine, Oncology, Pharmacology +11

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials

Chen Hu, Meihua Wang, Cai Wu et al. · JAMA Network Open · 2021 · 32 citations · Full text

Medicine, Immunology, Oncology +13